Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538893 | 0.92 | CNR1 (0.42) | CNR1CNR2CCR2ADRA1AADRA1B | |
| SCHEMBL2543516 | 0.91 | CNR1 (0.41) | CNR1CNR2CCR2ADRA1AADRA1B | |
| SCHEMBL2537280 | 0.91 | CNR1 (0.41) | CNR1CNR2CCR2ADRA1AADRA1B | |
| SCHEMBL2537282 | 0.91 | CNR1 (0.41) | CNR1CNR2CCR2ADRA1AADRA1B | |
| SCHEMBL2537645 | 0.91 | CNR1 (0.47) | CNR1CNR2PRKCZPOLBPDE5A | |
| SCHEMBL2536110 | 0.91 | CNR1 (0.50) | CNR1CNR2PRKCZPOLB | |
| SCHEMBL2536781 | 0.90 | CNR1 (0.48) | CNR1CNR2ADRA1AADRA1BACLY | |
| SCHEMBL2536787 | 0.90 | CNR1 (0.48) | CNR1CNR2ADRA1AADRA1BACLY | |
| SCHEMBL2543154 | 0.90 | CNR1 (0.48) | CNR1CNR2ADRA1AADRA1BACLY | |
| SCHEMBL2545423 | 0.90 | CNR1 (0.45) | CNR1CNR2PRKCZPOLBPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| EP-1911747-A1 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885CCR2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.